Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000596261 | SCV000701915 | uncertain significance | not provided | 2016-10-06 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854007 | SCV002116385 | uncertain significance | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2022-02-10 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 497422). This variant has not been reported in the literature in individuals affected with CACNA1A-related conditions. This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 2103 of the CACNA1A protein (p.Arg2103Lys). |